Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of TC-5214 monotherapy in major depressive disorder with inadequate antidepressant response
jRCT2080221501Phase 2
- Sponsor
- AstraZeneca
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmecamylamine in major depressive disorder (MDD) (4 arms), sponsored by AstraZeneca.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221501.